| Income statement (USD) | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 | FY 2019 ended Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Research and development | 854.3K | 1.19M | 8.24M | 12.84M | 10.37M | 12.45M |
| Interest expense | 1.6K | 1.6K | 2.1K | 39.1K | 50.5K | 105.9K |
| Net income | 7.06M | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M |
From Addex Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.